Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Daratumumab Versus Active Monitoring in High-risk Smoldering Multiple Myeloma
2023-507143-11-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised trial of daratumumab in smoldering multiple myeloma (SMM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Nov 2023; status: completed.
02
Drugs
daratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2023-507143-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507143-11-00.